English High Court denies Mylan a stay in Neurim litigation
02-11-2021
English appeals court refuses Neurim injunction for insomnia drug
26-06-2020
Questions on Neurim scope remain post-SPC ruling, say lawyers
25-03-2019
ricochet64 / Shutterstock.com
Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Neurim, Mylan, insomnia, Flynn, generic, patent, novel, obvious, prior art, melatonin
